Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month Low – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price reached a new 52-week low during trading on Tuesday . The stock traded as low as $12.98 and last traded at $13.97, with a volume of 141904 shares trading hands. The stock had previously closed at $14.81.

Rapport Therapeutics Trading Down 5.7 %

The firm has a 50-day moving average of $20.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RAPP. JPMorgan Chase & Co. purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter valued at $83,000. Barclays PLC raised its position in Rapport Therapeutics by 36.8% in the third quarter. Barclays PLC now owns 12,863 shares of the company’s stock worth $264,000 after acquiring an additional 3,463 shares during the period. Geode Capital Management LLC purchased a new position in Rapport Therapeutics in the third quarter valued at about $4,133,000. State Street Corp bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at approximately $1,189,000. Finally, Maven Securities LTD purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $613,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.